Scientific Collaboration in Clinical PharmacologyNCT07115680
Where Did the Authors Work When They Conducted Their Clinical Pharmacology Studies?
An observational study of Scientific Collaboration in Clinical Pharmacology, run by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz at 1 site in Spain.
Trial summary
It is unknown in which countries the clinical pharmacology studies published in leading specialized journals were conducted. The hypothesis is that studies in this specialty tend to be conducted and published by authors from a single country. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Scientific Collaboration in Clinical Pharmacology
- What is being tested?
- human participants, data or material
- How many people
- 503 participants
- Where
- 1 siteSpain
- Study dates
- 15 Sep 2025to 30 Nov 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: All original research articles published in the six top clinical pharmacology hybrid journals
Who may be able to join
- Articles on human participants, data or material. Original articles, short reports, research letters.
Who cannot join
- In vitro studies, animal studies. Editorials, letters, commentaries, perspectives.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Health Research Institute Fundación Jiménez Díaz
Madrid, Madrid, 28036
About this study
Official title: Countries Where the Main Authors and Their Collaborators of Recently Published Clinical Pharmacology Studies Worked
It is unknown in which countries the clinical pharmacology studies published in leading specialized journals were conducted. The hypothesis is that studies in this specialty tend to be conducted and published by authors from a single country. This analysis aims to describe the number of collaborators and the countries in which they worked, using the Nature Index concept of "share."
Read the detailed description
Original articles (full reports, short communications, research letters) on human participants, data, or material published in the seven top (as per Journal Citations Report 2024 Impact Factor) clinical pharmacology hybrid journals linked to clinical pharmacology professional societies will be included. Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first. The country of the main authors (first author/last author) and the countries where all the contributors listed in the article's byline worked will be recorded. Collaboration index and degree of collaboration will be calculated. The contribution of all countries will be calculated using the Nature index's "share" concept.Depending on whether a high percentage of articles are written by authors from the same country as a given journal (and scientific society), the need to adjust the results to reflect a situation closer to reality in terms of the importance of different countries in the publication of the articles evaluated will be assessed. As a proxy, the relevance of each country in contributing to clinical pharmacology research will be calculated by multiplying the "share" score by the JCR impact factor of each journal and adding the scores obtained from the seven journals. In addition, In addition, following slightly modified terminology used by ClinicalTrials.gov, the type of sector (industry, government institutions, and 'Others') will also be recorded to help characterize the studies evaluated. However, the 'Others' category will be classified into hospitals, universities, and research centers. Funding will be recorded as public, private, and public-private.
- Being tested
- human participants, data or material
- Keywords
- Clinical pharmacology, studies on humans, recently published
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
human participants, data or materialOther
Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies
| Study group | Role | What they receive |
|---|---|---|
| Single-country studies | Multinational studies Receives: Other: human participants, data or material |
What is being measured
The primary outcome is the main question the study is designed to answer.
countries where authors conducted their study
The country of the principal authors and of all collaborators will be registered following Nature Index 'share' concept
Measured: Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2025
- Study start15 Sep 2025
- Primary completion4 Nov 2025
- Study completion30 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Scientific Collaboration in Clinical PharmacologyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 503 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rafael Dal-Re, MD, PhD, MPH, Principal investigator, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07115680
- Sponsor's protocol ID
- IIS-FJD-RDR-2025-001
- Status last verified
- Dec 2025
- First submitted
- 4 Aug 2025
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: All data to be used in this study are in the public domain.
Publications
Dal-Re R, Llanos L, Mahillo-Fernandez I. Contribution of Countries and International Collaboration in Clinical Pharmacology Research. A Cross-Sectional Bibliometric Study of Six Top Ranked Specialty Society Journals. Basic Clin Pharmacol Toxicol. 2026 Aug;139(2):e70269. doi: 10.1111/bcpt.70269.
PubMed 42387320
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Countries Where the Main Authors and Their Collaborators of Recently Published Clinical Pharmacology Studies Worked
- ClinicalTrials.gov ID
- NCT07115680
- Acronym / sponsor ID
- IIS-FJD-RDR-2025-001
- Keywords
- Clinical pharmacology, studies on humans, recently published
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 503 participants (actual)
- Lead sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez DíazUniversity, hospital or other
- Study start
- 15 Sep 2025 (actual)
- Primary completion
- 4 Nov 2025 (actual)
- Study completion
- 30 Nov 2025 (actual)
- First posted
- 11 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is unknown in which countries the clinical pharmacology studies published in leading specialized journals were conducted. The hypothesis is that studies in this specialty tend to be conducted and published by authors from a single country. This analysis aims to describe the number of collaborators and the countries in which they worked, using the Nature Index concept of "share."
Detailed description
Original articles (full reports, short communications, research letters) on human participants, data, or material published in the seven top (as per Journal Citations Report 2024 Impact Factor) clinical pharmacology hybrid journals linked to clinical pharmacology professional societies will be included. Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first. The country of the main authors (first author/last author) and the countries where all the contributors listed in the article's byline worked will be recorded. Collaboration index and degree of collaboration will be calculated. The contribution of all countries will be calculated using the Nature index's "share" concept.Depending on whether a high percentage of articles are written by authors from the same country as a given journal (and scientific society), the need to adjust the results to reflect a situation closer to reality in terms of the importance of different countries in the publication of the articles evaluated will be assessed. As a proxy, the relevance of each country in contributing to clinical pharmacology research will be calculated by multiplying the "share" score by the JCR impact factor of each journal and adding the scores obtained from the seven journals. In addition, In addition, following slightly modified terminology used by ClinicalTrials.gov, the type of sector (industry, government institutions, and 'Others') will also be recorded to help characterize the studies evaluated. However, the 'Others' category will be classified into hospitals, universities, and research centers. Funding will be recorded as public, private, and public-private.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single-country studies | – | Other: human participants, data or materialMultinational studies |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All original research articles published in the six top clinical pharmacology hybrid journals
Key inclusion criteria (1 listed)
- Articles on human participants, data or material. Original articles, short reports, research letters.
Key exclusion criteria (1 listed)
- In vitro studies, animal studies. Editorials, letters, commentaries, perspectives.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| human participants, data or materialArticles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies | Other | Single-country studies |
Primary outcome
countries where authors conducted their study
Time frame: Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first
The country of the principal authors and of all collaborators will be registered following Nature Index 'share' concept
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
- Results publication: PubMed 42387320Dal-Re R, Llanos L, Mahillo-Fernandez I. Contribution of Countries and International Collaboration in Clinical Pharmacology Research. A Cross-Sectional Bibliometric Study of Six Top Ranked Specialty Society Journals. Basic Clin Pharmacol Toxicol. 2026 Aug;139(2):e70269. doi: 10.1111/bcpt.70269.
- Individual participant dataSharing planned: No. All data to be used in this study are in the public domain.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rafael Dal-Re, MD, PhD, MPH principal investigator
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Scientific Collaboration in Clinical Pharmacology, run by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
countries where authors conducted their study (time frame: Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07115680, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.